Hit games are a weird thing. They can sometimes come out of nowhere, and sometimes can be considered an inevitability. Many thought games such as Grand Theft Auto V by Take-Two Interactive (NASDAQ:TTWO) or any version of Call of Duty by Activision (NASDAQ:ATVI) would undoubtedly do very well and would likely be hits. Others took the market by surprise, Pok茅mon Go by Niantic/Nintendo (OTCPK:NTDOY) and Kim Kardashian Hollywood by Glu Mobile (NASDAQ:GLUU) come to mind. In general, it seems, mobile games have a greater propensity to come from the flank, becoming hit games to the surprise of even the most learned gaming experts. Maybe it has something to do with the mobile form factor, or maybe it’s the sheer amount of capital thrown at hit console games nearly guaranteeing they will be successful.
The mobile battlefield is full of games that came out of nowhere, Candy Crush, Clash of Clans, Summoners War, Episode – Choose Your Story and more recently, Archery King. The hits of tomorrow on this field are potentially not even out yet, at the very least, not a “hit” game yet. Mobile gaming executives have tried their hardest; they don’t want their industry to be viewed as hit-driven. No, they try to sell the portfolio of games narrative as much as investors have the patience to hear about it. Investors don’t seem to care. A nice solid portfolio is great but when the portfolio often produces ever-diminishing revenue quarter after quarter investors become tired of hearing how great a company’s “portfolio” might be. What we have seen in the industry are names that investors have become tired with, picked off by larger, more established gaming companies that see the value.
Hot Value Stocks For 2018: Nabriva Therapeutics AG(NBRV)
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading
Hot Value Stocks For 2018: S&W Seed Company(SANW)
- [By Ethan Ryder]
S&w Seed (NASDAQ:SANW) – Equities researchers at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for S&w Seed in a research note issued to investors on Thursday, May 10th. B. Riley analyst S. Sherbetchyan now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. B. Riley has a “Buy” rating and a $5.50 price objective on the stock.
Hot Value Stocks For 2018: Genomic Health, Inc.(GHDX)
- [By Logan Wallace]
Genomic Health (NASDAQ:GHDX) – Equities researchers at Piper Jaffray issued their Q2 2018 earnings per share (EPS) estimates for shares of Genomic Health in a research report issued on Wednesday, May 2nd. Piper Jaffray analyst W. Quirk expects that the medical research company will post earnings of $0.06 per share for the quarter. Piper Jaffray has a “Hold” rating and a $33.00 price target on the stock. Piper Jaffray also issued estimates for Genomic Health’s Q3 2018 earnings at $0.11 EPS, Q4 2018 earnings at $0.14 EPS, FY2018 earnings at $0.44 EPS, Q1 2019 earnings at $0.16 EPS, Q2 2019 earnings at $0.18 EPS, Q3 2019 earnings at $0.12 EPS, Q4 2019 earnings at $0.15 EPS and FY2019 earnings at $0.62 EPS.
- [By Brian Orelli]
Cancer-test maker Genomic Health (NASDAQ:GHDX) started the year on a high note, posting double-digit revenue growth, and would have turned a profit if not for an $8.5 millionone-time charge for stopping development of the Oncotype SEQ Liquid Select test, which was announced on the last quarterly call.